Zymeworks (ZYME) news
Recent news
ZymeWorks Inc.: Truist Securities raises target price to $34 from $32
Truist Securities has raised its price target for Zymeworks Inc. (NASDAQ: ZYME) to $34 from $32, reflecting a positive outlook on the biotechnology company’s recent developments and market performance. The adjustment comes amid ongoing analyst activity, with several firms maintaining or initiating…
AInvest Wire · Oct 7, 2026ZymeWorks Inc.: TD Cowen reinstates coverage with buy rating; price target $34
TD Cowen has reinstated coverage of ZymeWorks Inc. (NASDAQ: ZYME) with a "Buy" rating and a price target of $34 per share. The move reflects renewed analyst interest in the biotechnology firm following recent developments in its therapeutic pipeline and strategic collaborations. ZymeWorks, which…
AInvest Wire · Sep 29, 2026ZymeWorks Inc. FY2026 rev view $311.7 mln -- LSEG IBES data
AInvest Wire · Sep 28, 2026ZymeWorks sees yr rev, incl collab rev, $278M & $292M
AInvest Wire · Sep 28, 2026Zyme sees 2026 adj EBITDA $114M - $128M
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.